- Home
- RDHL vs INDP Comparison
RDHL vs INDP Comparison
Compare RDHL & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RDHL
- INDP
- Stock Information
- Founded
- RDHL 2009
- INDP 2000
- Country
- RDHL Israel
- INDP United States
- Employees
- RDHL N/A
- INDP N/A
- Industry
- RDHL Biotechnology: Pharmaceutical Preparations
- INDP Biotechnology: Pharmaceutical Preparations
- Sector
- RDHL Health Care
- INDP Health Care
- Exchange
- RDHL Nasdaq
- INDP Nasdaq
- Market Cap
- RDHL 11.2M
- INDP 12.1M
- IPO Year
- RDHL N/A
- INDP N/A
- Fundamental
- Price
- RDHL $7.08
- INDP $1.14
- Analyst Decision
- RDHL
- INDP Strong Buy
- Analyst Count
- RDHL 0
- INDP 2
- Target Price
- RDHL N/A
- INDP $8.50
- AVG Volume (30 Days)
- RDHL 14.3K
- INDP 305.3K
- Earning Date
- RDHL 11-19-2024
- INDP 11-12-2024
- Dividend Yield
- RDHL N/A
- INDP N/A
- EPS Growth
- RDHL N/A
- INDP N/A
- EPS
- RDHL N/A
- INDP N/A
- Revenue
- RDHL $3,707,000.00
- INDP N/A
- Revenue This Year
- RDHL $224.90
- INDP N/A
- Revenue Next Year
- RDHL $82.69
- INDP N/A
- P/E Ratio
- RDHL N/A
- INDP N/A
- Revenue Growth
- RDHL N/A
- INDP N/A
- 52 Week Low
- RDHL $6.80
- INDP $1.03
- 52 Week High
- RDHL $82.00
- INDP $3.10
- Technical
- Relative Strength Index (RSI)
- RDHL 29.71
- INDP 42.20
- Support Level
- RDHL $7.98
- INDP $1.11
- Resistance Level
- RDHL $7.36
- INDP $1.31
- Average True Range (ATR)
- RDHL 0.37
- INDP 0.10
- MACD
- RDHL -0.12
- INDP -0.01
- Stochastic Oscillator
- RDHL 0.00
- INDP 14.34
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's pre-clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.